JACC: Clinical Electrophysiology Publishes 12-Month Outcomes from Field Medical’s First-in-Human Field PULSE Trial: 94.2% Per-Vein PVI Durability with Optimized Waveform
Late-breaking HRX data advance Field Medical’s “instantaneous ablation” workflow and expand the clinical evidence for high-voltage focal PFA with the FieldForce™ PFA System ATLANTA and CARLSBAD, Calif., Sept. 20, 2026 /PRNewswire/ — Field Medical, Inc.,
